AltaThera Pharmaceuticals

Executive Summary

AltaThera Pharmaceuticals is a precision medicine company leveraging model-informed drug development (MIDD) to optimize cardiovascular therapies. Its lead candidate, Sotalol IV, is a novel intravenous formulation designed to shorten hospital stays for atrial fibrillation patients by enabling safer, more individualized dosing. The company's approach bridges the gap between scientific innovation and clinical decision-making, potentially reducing healthcare costs and improving patient outcomes. With a focus on repurposing existing drugs through advanced modeling, AltaThera aims to capture a niche in the atrial fibrillation market, which is underserved by current IV antiarrhythmics. The company is privately held and based in Chicago, positioning itself as a pioneer in MIDD-driven drug development.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval Decision for Sotalol IV70% success